{"id":389796,"date":"2022-07-26T00:00:00","date_gmt":"2022-07-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2022-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2022\/"},"modified":"2026-04-15T23:19:17","modified_gmt":"2026-04-15T23:19:17","slug":"dlsfon0015-2022-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2022-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2022\/","title":{"rendered":"Gastroesophageal Cancer | Disease Landscape &#038; Forecast | G7 | 2022"},"content":{"rendered":"<p>The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint inhibitor combination therapies. We expect that label expansions of Opdivo (Bristol Myers Squibb) and Keytruda (Merck &#038; Co.), as well as approvals of other programmed death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) inhibitors, will continue to reshape the human epidermal growth factor receptor-2 (HER2)-negative gastroesophageal cancer market in the coming years. Immune checkpoint inhibitors in combination with HER2-targeted agents and chemotherapy, and the anti-HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo \/ AstraZeneca) are poised to expand treatment options for HER2-positive patients. Other treatments are targeting niche biomarkers (e.g., claudin18.2, FGFR2b) and are set to provide novel treatment options for select gastroesophageal cancer patients. Given the intense late-phase pipeline activity, we anticipate the approval of several new therapies for gastroesophageal cancer during the forecast period.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>How is gastroesophageal cancer segmented by subpopulation, and how will the recent drug approvals and label expansions to the various subpopulations impact the market?<\/li>\n<li>What are the key current therapies in gastroesophageal cancer, and how are they positioned in the treatment algorithm?<\/li>\n<li>Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer market?<\/li>\n<li>What are the drivers and constraints in the gastroesophageal cancer market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<p>Additionally, Disease Landscape &#038; Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389796","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-esophageal-cancer","biopharma-therapy-areas-oncology","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389796\/revisions"}],"predecessor-version":[{"id":576225,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389796\/revisions\/576225"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}